Cardiovascular and Metabolic Alterations in Mice Lacking Both beta 1- and beta 2-Adrenergic Receptors*

Daniel K. RohrerDagger , Andrzej Chruscinski§, Eric H. Schaubleparallel , Daniel Bernsteinparallel , and Brian K. Kobilka§**

From the Dagger  Department of Molecular Pharmacology, Roche Bioscience, Palo Alto, California 94304, the § Howard Hughes Medical Institute, Stanford University, and the parallel  Division of Pediatric Cardiology, Department of Pediatrics, Stanford University, Stanford, California 94305

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The activation state of beta -adrenergic receptors (beta -ARs) in vivo is an important determinant of hemodynamic status, cardiac performance, and metabolic rate. In order to achieve homeostasis in vivo, the cellular signals generated by beta -AR activation are integrated with signals from a number of other distinct receptors and signaling pathways. We have utilized genetic knockout models to test directly the role of beta 1- and/or beta 2-AR expression on these homeostatic control mechanisms. Despite total absence of beta 1- and beta 2-ARs, the predominant cardiovascular beta -adrenergic subtypes, basal heart rate, blood pressure, and metabolic rate do not differ from wild type controls. However, stimulation of beta -AR function by beta -AR agonists or exercise reveals significant impairments in chronotropic range, vascular reactivity, and metabolic rate. Surprisingly, the blunted chronotropic and metabolic response to exercise seen in beta 1/beta 2-AR double knockouts fails to impact maximal exercise capacity. Integrating the results from single beta 1- and beta 2-AR knockouts as well as the beta 1-/beta 2-AR double knock-out suggest that in the mouse, beta -AR stimulation of cardiac inotropy and chronotropy is mediated almost exclusively by the beta 1-AR, whereas vascular relaxation and metabolic rate are controlled by all three beta -ARs (beta 1-, beta 2-, and beta 3-AR). Compensatory alterations in cardiac muscarinic receptor density and vascular beta 3-AR responsiveness are also observed in beta 1-/beta 2-AR double knockouts. In addition to its ability to define beta -AR subtype-specific functions, this genetic approach is also useful in identifying adaptive alterations that serve to maintain critical physiological setpoints such as heart rate, blood pressure, and metabolic rate when cellular signaling mechanisms are perturbed.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The beta -adrenergic receptors (beta 1-, beta 2-, and beta 3-AR)1 belong to the superfamily of G-protein-coupled receptors (1). Both sequence comparisons and functional studies suggest that these three receptors share many structural and mechanistic features (2). Agonist stimulation of cloned and exogenously expressed beta -ARs has demonstrated that all three subtypes can couple through Galpha s to stimulate adenylate cyclase activity (3-5). Despite these common structural and functional properties, however, individual beta -AR subtypes in vivo remain as distinct therapeutic targets due to a number of factors that actually serve to distinguish them. These distinctions include tissue-specific expression patterns, the ability to couple to different G-proteins, pharmacological heterogeneity, and differences in agonist-dependent desensitization (6, 7).

beta -AR subtypes can be distinguished pharmacologically by synthetic as well as natural ligands. The beta 1-AR subtype shows little preference for epinephrine or norepinephrine, whereas the beta 2-AR preferentially interacts with epinephrine (8, 9). More recent experiments demonstrate that the beta 3-AR (previously termed "atypical") preferentially interacts with norepinephrine over epinephrine. Synthetic subtype-selective agents have been developed which display much greater selectivity than these endogenous catecholamines. Some typical examples of these would include the antagonists CGP20712A (beta 1-AR-selective) and ICI118551 (beta 2-AR-selective) and the agonist CL316243 (beta 3-AR-selective). Such synthetic compounds have proven invaluable for studying beta -AR pharmacology and function (2, 10).

In vivo, beta -ARs are known to modulate a wide range of physiological processes, from cardiac chronotropy and inotropy to vascular and smooth muscle tone, metabolism, and behavior. Functional assignment of beta -AR subtype functions using pharmacological tools suggests that the beta 1-AR is the predominant subtype regulating heart rate and contractility, although at least in the human, beta 2-ARs are also thought to participate. beta 2-ARs have been thought to be the predominant subtype mediating the vascular smooth muscle relaxant properties of beta -AR agonists. The beta 3-AR was initially identified and proposed to be the major beta -AR subtype controlling lipolysis in adipose tissue. Although these functional divisions are not absolute, they appear to be well conserved across species and serve as a convenient framework for beta -AR classification. However, defining beta -AR subtype-specific functions in vivo can present significant challenges. Some subtype-selective agents display non-ideal behavior in vivo, either due to poor biodistribution or cross-reactivity with unrelated receptors. Gene disruption, or "knockout" experiments, has proven to be a useful approach in defining adrenergic receptor function in vivo. To date, this technique has been used to disrupt expression of all three alpha 2-AR subtypes, the alpha 1b-AR, the beta 1-, and the beta 3-ARs (11-16), and most recently, the beta 2-AR (17). When the pharmacologic tools outlined above are used in conjunction with genetic techniques, the power to reveal novel functions and mechanisms of action can be greatly enhanced.

Given the prominent role of beta -AR signaling in the maintenance of normal physiology in vivo, we sought to test the functional consequences of beta -AR gene disruption via a combinatorial approach. In the companion article (17), the functional consequences of beta 2-AR disruption are described. We have previously described the functional consequences of beta 1-AR gene disruption (13, 18). We have now produced mice that lack both beta 1- and beta 2-ARs. The role of these two beta -AR subtypes and the inferred role of the remaining beta 3-AR subtype in cardiovascular physiology and metabolism are reported here.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Generation of beta -AR Knockout Mice-- The generation of beta 1-AR knock-out mice has been previously described (13). Briefly, disruption of the beta 1-AR gene was achieved using a positive-negative selection strategy to effect homologous recombination in the R1 embryonic stem cell line, using a targeting construct in which over 90% of the coding sequence was deleted. The strain background of beta 1-AR knockout mice was a mixture of 129SvJ, C57Bl6/J, and DBA/2 which is less prone to the prenatal mortality previously described (13). The targeting strategy used to create beta 2-AR knockout mice is described in the companion article (17) and is based on a similar positive-negative selection scheme and homologous recombination in the R1 embryonic stem cell line. Combination beta 1/beta 2-AR double knockouts were generated by mating beta 2-AR homozygous knockouts (on a combined 129SvJ and FVB/N mouse strain background) to homozygous beta 1-AR knockouts. The resulting F1 generation of compound heterozygotes was subsequently intercrossed to generate F2 mice with all possible combinations of beta 1- and beta 2-AR gene disruptions. According to Mendelian inheritance, 1/16 of progeny were predicted to be homozygous-deficient for beta 1- and beta 2-AR, and 1/16 of progeny were predicted to be wild type for both beta 1- and beta 2-AR (see Table I). The F2 beta 1/beta 2-AR double knockouts were bred to produced to double knockouts used in our experiments. The wild type F2 mice were bred to produce wild type controls. Thus, the overall strain contributions between wild type and beta 1/beta 2-AR double knockouts were equivalent. Mice were genotyped for both beta 1- and beta 2-AR disruptions by Southern blotting of mouse tail biopsies (13, 17).

Mouse Instrumentation-- Catheters were surgically implanted in either the left carotid artery or the left carotid artery plus the left jugular vein under isoflurane anesthesia. Briefly, anesthesia was induced with 3% (v/v) isoflurane in oxygen using an isoflurane vaporizer (Airco Inc., Madison, WI), and then induction was maintained at 1.25-1.75% while monitoring the responsiveness of the animal. The vessels were cannulated with a stretched Intramedic PE10 polyethylene catheter (Clay Adams, Parsippany, NJ), which was filled with heparinized normal saline, sutured in place, and tunneled to the back. Blood pressure was measured using a DTX Plus pressure transducer (Spectramed, Oxnard, CA) amplified with a Gould 8-channel recorder, and the analog pressure was digitized using a Data Translation Series DT2801 analog-digital converter (Marlboro, MA). Digital signals were analyzed and stored using Crystal Biotech Dataflow data acquisition software (Crystal Biotech, Hopkington, MA). Heart rate measurements were determined on-line and were derived from the pressure recordings. Drugs were infused through the arterial catheter as a bolus in a volume of 1-3 µl/g. (-)-Isoproterenol hydrochloride (3 µg/kg), atropine sulfate (1 mg/kg), epinephrine bitartrate (3 µg/kg), and sodium nitroprusside (30 µg/kg) were purchased from Sigma. CL316243 (100 µg/kg) was a kind gift of Wyeth Ayerst Laboratories (Philadelphia, PA).

Assessment of Ventricular Function-- A 1.4 French micromanometer-tipped Millar pressure transducer (Millar Instruments, Houston, TX) was advanced into the left ventricle via the right carotid artery under isoflurane anesthesia (see above). Correct placement of the catheter in the ventricle was judged by loss of the arterial waveform and transition to a waveform with similar peak systolic pressure, but diastolic pressures with minima in the 0-5 mm Hg range. Following correct placement, a jugular venous catheter was placed via the left jugular vein and advanced ~1 cm. The surgical incision was then sutured closed with 4-0 silk, and the mouse was allowed to stabilize for 10-15 min at 2.5% isoflurane. Pressure recordings were measured using a MacLab 8S digitizer/amplifier (MacLab, Milford, MA), recorded, and analyzed using MacLab/s version 3.5 software on a Macintosh 3400c. "Anesthetized" recordings of ventricular function were taken during a 1-min interval at the end of this 10-15-min equilibration period, at 2.5% isoflurane. Isoflurane anesthesia was then reduced in a stepwise fashion, from 2.5 to 1.25%, and mice were allowed to stabilize for 10 min. Following this period, isoflurane anesthetic was turned off, and the mouse was removed from the anesthetic nose cone and placed on its back. Upon self-righting (or the "awakening" state), mice were quickly euthanized with an intravenous dose of avertin. Awakening recordings of ventricular function were taken in the 30-60 s prior to the righting response.

Exercise Protocols, Metabolic Measurements-- Mice were subjected to either constant or graded treadmill exercise, using a Columbus Instruments Simplex II metabolic rodent treadmill, fitted with Oxymax oxygen and carbon dioxide gas analyzers (Columbus Instruments, Columbus, OH). For graded exercise, mice were placed in the exercise chamber and allowed to equilibrate (usually 30-60 min). Treadmill activity was initiated at 3.5 m/min, 0° inclination, and increased to 5 m/min, 2° inclination 3 min later. Treadmill speed and inclination were then increased by 2.5 m/min and 2° inclination every 3 min thereafter. Pre-operatively, mice were initially subjected to this protocol, with regular stepwise increases until mice stopped running from exhaustion. Post-operatively, mice were run to a final end point of 20 m/min and 14° inclination. We have previously shown linear relationships between heart rate, VO2 and VCO2 during graded treadmill exercise in mice (19).

In Vitro Cardiac Physiology-- The right ventricular free wall was dissected away from the left ventricle and interventricular septum, and silk sutures were tied at both ends of the long axis. Ventricles were placed in an oxygenated 32 °C tissue bath containing modified Krebs solution (118 mM NaCl, 5.4 mM KCl, 2.5 mM CaCl2, 0.57 mM MgSO4, 1.0 mM Na2HPO4, 2.5 mM NaHCO3, 11.1 mM D-glucose). Ventricles were paced at 3.3 Hz by use of a Grass stimulator (30-ms pulse duration, 8-15 V). Signals from isometric force transducers were amplified and digitized with a MacLab 8S series amplifier and fed to MacLab/s version 3.5 software running on a Macintosh 3400c to determine twitch amplitude.

For spontaneously beating atria, right and left atria were dissected free of ventricular tissue, and both atrial appendages were tied with 4-0 silk sutures. These were placed in an oxygenated 32 °C tissue bath, where isometric force transduction and rate were monitored as above.

Radioligand Binding Assays-- Ventricular homogenates were prepared by Polytron homogenization of whole organs in 5 mM Tris-Cl, 5 mM EDTA, pH 7.4, followed by centrifugation at 10,000 × g. The resultant pellet was resuspended in 1× binding buffer (for alpha -adrenergic receptor binding, 150 mM NaCl, 50 mM Tris-Cl, 5 mM EDTA, pH 7.4; for muscarinic receptor binding, 75 mM Tris-Cl, 12.5 mM MgCl2, 1 mM EDTA, pH 7.4), and protein concentration was determined. For saturation binding, 50-100 µg of homogenate protein was used in a 500-µl reaction containing 300 pM 125I-2-[beta -(4-hydroxyphenyl)-ethyl-aminomethyl]tetralone or 300 pM [3H]N-methyl scopolamine (both from NEN Life Science Products). Nonspecific binding was performed in duplicate with 20 µM prazosin (Research Biochemicals, Natick, MA) or 5 µM atropine sulfate, respectively (Sigma). All binding reactions were carried out at room temperature for ~2 h prior to vacuum filtration onto Whatman GF-C filters and determination of membrane-bound radioligand.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Generation and Recovery of beta -AR Knockout Mice-- The generation and viability of beta 1-AR knockout mice (beta 1-AR -/-) have been described previously (13). Briefly, homozygous beta 1-AR knockouts derived from heterozygote:heterozygote matings (beta 1-AR +/- × beta 1-AR +/-) are recovered at an unexpectedly low frequency as predicted from Mendelian inheritance, although this effect can be ameliorated if the beta 1-AR gene disruption is bred onto a multiple strain background. As described by Chruscinski et al. (17), the recovery of homozygous beta 2-AR knockouts (beta 2-AR -/-) is in accord with expected Mendelian frequencies.

Crosses were carried out between homozygous beta 1-AR knock-outs and homozygous beta 2-AR knockouts to generate compound heterozygotes (beta 1-AR +/-:beta 2-AR +/-, see "Materials and Methods"), and these in turn were intercrossed to generate homozygous beta 1- and beta 2-AR double knockout mice (beta 1-AR -/-:beta 2-AR -/-). The expected frequency of recovering double knockout mice from compound heterozygote matings is 1 out of 16 or 6.25%. The observed frequency among weanlings was 7.23%, well within the expected range. Table I lists the expected and observed frequencies among the nine possible genotypes arising from the compound heterozygote intercrosses. The chi 2 distribution suggests that there are no significant deviations from Mendelian expectations either among individual genotypes or the group as a whole (chi 2 = 9.38 with 8 degrees of freedom, p = 0.29), although beta 1-AR knockouts (beta 1-AR -/-:beta 2-AR +/+) appear to be less well represented, in accord with our previous findings (13). Double knockout:double knockout matings were subsequently performed to generate mice for the studies reported here. Litter size, maternal behavior, and pup viability all appeared to be normal in this group.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Frequency of viable pups at weaning from beta 1 +/-:beta 2 +/- × beta 1 +/-:beta 2 +/- intercrosses
The nine possible genotypes are listed together with the number of recovered viable pups. Expected values are derived from Mendelian inheritance patterns; chi 2 = Sigma  d2/E, where d is expected number - observed number, and E is expected number, with 8 degrees of freedom.

Basal Cardiovascular Function-- Basal cardiovascular parameters were measured in awake, unrestrained mice by use of indwelling carotid arterial catheters. As seen in Fig. 1, neither baseline heart rate (range 400-470 beats/min) nor mean arterial blood pressure (range 115-125 mm Hg) are significantly different when comparing wild type mice (beta 1-AR +/+:beta 2-AR +/+) to double knockouts (beta 1-AR -/-:beta 2-AR -/-).


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 1.   Basal cardiovascular indices in wild type and beta 1/beta 2 knockout mice. Conscious, unrestrained mice instrumented with carotid arterial catheters were monitored for both heart rate (in beats per min (bpm)), and mean arterial blood pressure (mm Hg). 12 mice of each genotype were studied. beta 1/beta 2KO refers to beta 1/beta 2-AR double knockout mice.

Response to Catecholamines-- Both isoproterenol and epinephrine were administered to wild type and beta 1/beta 2-AR double knockout mice. The grouped response to these agents is shown in Fig. 2A. Whereas the non-selective beta -AR agonist isoproterenol (3 µg/kg) elicits robust chronotropic and hypotensive responses in wild types, both of these responses are severely attenuated in beta 1/beta 2-AR double knockout mice. Of note, both responses are also significantly time-delayed in beta 1/beta 2-AR double knockouts in comparison to wild type responses. Furthermore, the small but significant increase in heart rate seen in double knockout mice in response to isoproterenol was attenuated by 93% in mice pretreated with the muscarinic antagonist atropine (1 mg/kg, data not shown), suggesting that the majority of this effect is due to the baroreflex, mediated by the vagus in response to the drop in blood pressure.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 2.   Cardiovascular response to catecholamines. A, isoproterenol (3 µg/kg) or epinephrine (3 µg/kg) were injected intra-arterially as a bolus to conscious unrestrained wild type mice (squares) or beta 1/beta 2 knockouts (filled circles) at the 2.5-min time point. The effects on heart rate and blood pressure are shown for these two agents, expressed as the change (Delta ) in beats/min (bpm) or mm Hg, respectively (wild type, n = 10; beta 1/beta 2KO, n = 9). B, the percentage contribution of individual beta -AR subtypes is inferred from a comparison of beta 1-, beta 2-, and beta 1/beta 2-AR knockouts. As above, the response to isoproterenol (1-3 mg/kg intra-arterially) is shown as a percentage of the wild type response for either the increase in heart rate or the decrease in mean blood pressure. The dotted line indicates 100% of the wild type response (, beta 1 knockouts, n = 24; black-square, beta 2 knockouts, n = 16; , beta 1/beta 2 knockouts, n = 9). Data for beta 1 knockouts were adapted from Rohrer et al. (18); data for beta 2 knock-outs were adapted from Chruscinski et al. (17). Responses in all groups except heart rate in beta 2 knockouts are significantly decreased (p <=  0.01) in comparison to the wild type response. For heart rate responses, all genotypes display significantly different heart rate responses from each other (p <=  0.02). For blood pressure response, both beta 1 and beta 2 knock-outs are significantly different from beta 1/beta 2 knockouts (p <=  0.01).

The effect of epinephrine (3 µg/kg) on beta 1/beta 2-AR double knockouts is seen in the right-hand panel of Fig. 2A. This endogenous catecholamine is a mixed, non-selective alpha -AR and beta -AR agonist. In wild types, this dose of epinephrine elicits tachycardia and a biphasic blood pressure response consisting of an initial brief hypertension followed by a more prolonged hypotensive response. In contrast, ablation of beta 1- and beta 2-AR signaling in the double knockout appears to convert this mixed alpha - and beta -AR agonist into a selective alpha -AR agonist; these mice display concomitant bradycardia and a monophasic hypertensive blood pressure response. Again, the heart rate response to epinephrine seen in double knockouts appears to be predominantly due to baroreflex stimulation, as atropine pretreatment blocks 60% of this response (data not shown).

Fig. 2B is a compilation of the chronotropic and hemodynamic effects of isoproterenol on conscious and unrestrained beta 1-AR knockouts, beta 2-AR knockouts, and beta 1/beta 2-AR double knockouts. These are all displayed relative to the response seen in wild type mice (dotted line at 100%) and represent the peak chronotropic and vasodilatory responses obtained in each genotype, respectively. Based on these data, ~50% of the chronotropic response to isoproterenol is lost when the beta 1-AR is knocked out, whereas there is no detrimental effect on heart rate in beta 2-AR knockouts. The combined beta 1- and beta 2-AR deficiency reduces the chronotropic response by over 85%. In terms of the vasodilatory response to isoproterenol, there appears to be a graded and additive attenuation of the hypotensive response with loss of the beta 1-AR (20% reduction), beta 2-AR (35% reduction), and combined beta 1-/beta 2-AR (71% loss).

Hemodynamic Responses to the beta 3-AR Agonist CL316243-- The hemodynamic response to the beta 3-AR agonist CL316243 was tested in beta -AR knockout mice to clarify the role of the beta 3-AR in the regulation of peripheral vasodilatory responses in vivo. Infusion of the beta 3-AR-selective agonist was followed by infusion of the non-selective beta -AR agonist isoproterenol, to ascertain residual beta 1- and/or beta 2-AR responsiveness. Both drugs were used at doses that elicit maximal responses in vivo (19, 20). As can be seen in the top panel of Fig. 3, administration of CL316243 at 100 µg/kg to a wild type mouse leads to a gradual but sustained hypotensive response. Near-maximal responses to this agonist were observed after 10 min, at which time isoproterenol was infused. These results clearly show that a residual beta 1- and/or beta 2-AR vasodilatory response can be elicited by isoproterenol even while beta 3-ARs are maximally stimulated. The time course of beta 3-AR-mediated vasodilatation suggests that the duration of action as well as the time interval to peak response is much longer for the beta 3-AR response to CL316243 than for the beta 1/beta 2-AR response to isoproterenol. This appears to be unique to the response mediated by beta 3-ARs and not specific to CL316243, as isoproterenol given to beta 1/beta 2-AR double knockouts also exhibits a similar time lag (Fig. 2A).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 3.   Hemodynamic responsiveness to the beta 3-AR agonist CL316243 and the non-selective agonist isoproterenol. The upper panel is a representative blood pressure tracing of a wild type mouse given a single bolus injection of CL316243 (100 µg/kg). Ten minutes following injection of the beta 3-AR agonist, isoproterenol was given (3 µg/kg intra-arterially). The bar graph in the lower panel summarizes identically performed experiments for wild type, beta 1-, beta 2-, and beta 1/beta 2-AR knockouts. The hemodynamic effect of CL316243 at 10 min (just prior to Iso administration) is shown by the cross-hatched bars, and the additional effect of Iso (compared with the period just preceding Iso administration) is shown by the black bars. Wild type, n = 16; beta 1 knockouts (KO), n = 6; beta 2 knockouts, n = 9; beta 1/beta 2 knockouts, n = 7. For beta 2 knockouts, * indicates p <=  0.01 versus wild type. For beta 1/beta 2 knockouts, dagger  indicates p <=  0.01 versus wild type.

The bottom panel of Fig. 3 summarizes identically performed experiments on wild type, beta 1-, beta 2-, and combination beta 1-/beta 2-AR knockout mice. Interestingly, the response to the beta 3-AR agonist CL316243 alone was significantly augmented in the beta 1/beta 2-AR double knockouts. Furthermore, the effect of isoproterenol following beta 3-AR stimulation (residual response) revealed that mice lacking beta 1-ARs showed no deficit in the residual vasodilatory response, whereas loss of beta 2-ARs had a large impact on further vasodilatory responses. Surprisingly, when both beta 1- and beta 2-ARs were lacking, isoproterenol infusion actually had a small hypertensive effect. Such a response can be due to either injection artifact or cross-reactivity to alpha -ARs. In either case, these results suggest that all three beta -ARs can mediate vasodilatory responses in vivo and that an enhancement of beta 3-AR responsiveness is seen in mice lacking both beta 1- and beta 2-ARs.

Cardiovascular and Metabolic Responses to Exercise in the beta 1-/beta 2-AR Double Knockout-- We also tested the role of beta 1- and beta 2-AR signaling on the response to the physical stress of exercise. Knowing that beta -ARs are recruited during exercise to modulate heart rate, hemodynamics, airway conductance, and metabolic rate, we hypothesized that mice lacking both beta 1- and beta 2-ARs would be compromised in both exercise capacity as well as the cardiovascular and metabolic response to exercise. Using graded treadmill exercise (GTE) as a stimulus, where both speed and angle of inclination are progressively increased, both wild type mice and beta 1/beta 2-AR double knockouts were tested for total exercise capacity as well as the physiological response to fixed end point GTE. Total exercise capacity was measured as cumulative distance run in non-instrumented mice, with treadmill speed and angle of inclination increasing by 2.5 m/min and 2° every 3 min until mice stopped running from exhaustion. Physiological responses to fixed end point GTE were obtained by running instrumented mice to a final end point of 20 m/min and 14° inclination (see "Materials and Methods").

Experiments designed to test total exercise capacity showed no significant differences between wild types and beta 1/beta 2-AR double knockouts with respect to cumulative distance run. Wild type mice ran a total distance of 578.8 ± 33.3 m (n = 7), whereas beta 1/beta 2-AR double knockouts ran a total distance of 545.2 ± 30.0 m (n = 5). The metabolic response to GTE in the maximal exercise capacity experiment is shown in Fig. 4B, demonstrating that whereas both wild types and beta 1/beta 2-AR double knockouts have virtually identical levels of O2 consumption and CO2 production at rest, consistent deficits in both of these indices are revealed at all exercise levels in the double knockout. This metabolic deficit appears to result from the combined deficiency of beta 1- and beta 2-ARs, since neither the beta 1-AR knockout nor the beta 2-AR knockout display such deficits (17, 18). Interestingly, however, there are differences in total exercise capacity between wild type mice and beta 2-AR knockouts, with the beta 2-AR knockout demonstrating a slight enhancement of total exercise capacity and reduced respiratory exchange ratios (17). In contrast, beta 1-AR ablation has no effect on total exercise capacity (18).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 4.   Cardiovascular and metabolic response to exercise. Both wild type and beta 1/beta 2-AR knockouts were subjected to a GTE regimen (see "Materials and Methods"). A, the cardiovascular response to GTE was determined in instrumented mice, which were run to a final end point of 20 m/min and 14° inclination. Rec, recovery (10 min post-exercise). Wild type, n = 7. beta 1/beta 2 knockouts,, n = 6. For heart rate, wild type versus beta 1/beta 2 knockouts is significantly different (p <=  0.01 by two-way analysis of variance with repeated measures, excluding recovery). B, the metabolic response to GTE was monitored in non-instrumented mice, which were run to their voluntary limit. O2 consumption and CO2 production are expressed as ml/min/kg. Wild type, n = 7. beta 1/beta 2 knockouts, n = 5. Wild type mice are significantly different than beta 1/beta 2 knockouts in both O2 consumption and CO2 production (p <=  0.01 by two-way analysis of variance with repeated measures, up to 27.5 m/min treadmill speed).

The physiological response to GTE is seen in Fig. 4A. Both blood pressure and heart rate were monitored in resting and exercising mice by use of indwelling carotid arterial catheters. The normal response to increasing exercise workloads is a corresponding increase in heart rate (up to the maximally achievable rate of ~800 beats/min in the mouse). Both wild type and beta 1/beta 2-AR knockouts show workload-dependent increases in heart rate; however, the heart rate of beta 1/beta 2-AR mice was lower than the heart rate of wild type mice at all exercise levels (at rest, heart rate differences are not statistically significant between the two genotypes). The effect of exercise on mean peripheral arterial blood pressure is not different between these two groups. The loss of exercise-induced tachycardia is most likely the result of beta 1-AR ablation, as a virtually identical behavior is seen in beta 1-AR knockout mice (18), whereas beta 2-AR knockouts show no deficit in exercise-induced tachycardia (17).

Muscarinic and alpha 1-Adrenergic Receptor Density in Cardiac Membranes-- There is a well known functional interdependence between beta -ARs and muscarinic receptors in the heart, which represent the two major targets of cardiac sympathetic and parasympathetic stimulation, respectively. Additionally, the role of alpha 1-ARs either alone or in combination with beta -ARs is thought to be critical for both acute responsiveness to catecholamines, as well as in longer term adaptive or remodeling responses in the heart. We thus sought to test whether any gross alterations in either of these receptor families was apparent in beta 1/beta 2-AR double knockouts in comparison to wild types. Whereas muscarinic receptor density displayed a mild but significant reduction in double knockouts in comparison to wild types (28.9 ± 1.6 fmol/mg protein versus 33.6 ± 1.0 fmol/mg protein; n = 4 for both, p <=  0.05), alpha 1-AR density was not significantly affected by loss of both beta 1- and beta 2-ARs in comparison to wild types (50.3 ± 3.4 fmol/mg protein versus 54.1 ± 4.1 fmol/mg protein, respectively; n = 4 for both, p = not significant).

In Vitro Cardiac Responsiveness to G-protein-coupled Receptor Agonists-- The effect of various G-protein-coupled receptor agonists was tested in either spontaneously beating atrial preparations (chronotropic assay) or paced right ventricular strips (inotropic assay). These experiments were performed to investigate the efficacy of these compounds relative to beta -AR agonists, as well as to reveal any potential compensation for loss of beta -AR signaling that could be manifested as an altered response relative to wild type preparations. An additional utility of these experiments was the potential to reveal any compensation with an indirect mechanism of action, since several potential compensatory signaling pathways could exert their effects through modulating the release of catecholamines and subsequent activation of beta -ARs (21-23). The agonists tested included serotonin, angiotensin II, the beta 3-AR agonist CL316243, dopamine, histamine, the beta -AR agonist isoproterenol (Iso), and the alpha -AR agonist phenylephrine. As can be seen in Fig. 5, there were no significant differences between wild type and beta 1/beta 2-AR double knockout preparations in response to any of these drugs, with the exception of isoproterenol, which has robust effects on both atrial rate and ventricular contractility in wild type preparations but no effect in beta 1/beta 2-AR double knockout preparations. The lack of effect of isoproterenol in the double knockout is virtually identical to that seen in beta 1-AR knockout preparations (13), supporting the predominant role of beta 1-ARs in the regulation of murine heart rate and contractility. The concentration of agonist used in each of these experiments (see Fig. 5 legend) was designed to elicit a maximal effect, based on prior experiments. It is notable that neither CL316243 nor isoproterenol has any appreciable effect on either atria or ventricles from beta 1-/beta 2-AR double knockouts, given the purported negative coupling behavior of the beta 3-AR in human cardiac preparations (24).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 5.   In vitro chronotropic and inotropic responsiveness of wild type and beta 1/beta 2-AR knockout preparations. A variety of pharmacological agents was tested for their ability to alter chronotropy or inotropy in spontaneously beating atrial preparations or paced right ventricular preparations, respectively. The upper panel shows the chronotropic response to serotonin (5-HT, 1 µM), angiotensin II (A II, 0.1 µM), the beta 3-AR agonist CL316243 (CL, 1 µM), dopamine (DA, 1 µM), histamine (Hist, 1 µM), isoproterenol (Iso, 1 µM), and phenylephrine (Phen, 1 µM), and the lower panel displays the inotropic response to the same agents. Wild type, n = 3. beta 1/beta 2 knockouts, n = 5. All comparisons between wild type and beta 1/beta 2 knockouts are not significant with the exception of Iso (p <=  0.05 for both atrial rate and ventricular twitch response).

In Vivo Left Ventricular Contractility in Anesthetized and Awakening Mice-- Based on the observation that exercising beta 1/beta 2-AR double knockout mice can achieve similar workloads at reduced heart rates, we sought to test whether corresponding deficits were also present in the inotropic component of heart function in vivo, given the well known effects of beta -AR agonists to regulate cardiac contractility. These studies were performed in both anesthetized and awakening mice in an attempt to reduce the cardiodepressant effects of anesthesia, using micromanometer-tipped left ventricular catheters (see "Materials and Methods"). Fig. 6 shows representative tracings from two mice in both anesthetized and awakening states. Clearly both wild types and beta 1/beta 2-AR double knockouts show depressed cardiac contractility, both in terms of developed pressure and dP/dt (the first derivative of left ventricular pressure) in the anesthetized versus the awakening state. Furthermore, beta 1/beta 2-AR double knockouts show diminished positive and negative peak dP/dt values relative to wild type mice whether measured during anesthesia or during awakening. Table II summarizes the data from these experiments, with the finding that while both +dP/dt and -dP/dt were reduced in beta 1/beta 2-AR double knockouts relative to wild type mice (in both anesthetized and awakening states), there were no differences between wild types and double knockouts with respect to peak developed pressures in either state. There were also significant differences in heart rate between wild type and beta 1/beta 2-AR double knockouts both in the anesthetized and awakening states, which in turn may influence dP/dt values. Monitoring of left ventricular pressure was terminated after mice righted themselves. At this time, the intraventricular pressure measurements became very unreliable and prone to position effects making these measurements in fully awake mice untenable.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 6.   Left ventricular contractility in anesthetized and awakening mice. Micromanometer-tipped pressure-sensing catheters were advanced from the carotid to the left ventricle under anesthesia, measurements were taken, and mice were allowed to recover until self-righting became evident. Representative tracings from two mice are shown, in both the anesthetized and awakening state. Both the left ventricular pressure tracings (upper panels) and the first derivative of pressure, dP/dt (lower panels), are shown for a wild type and beta 1/beta 2-AR knockout mouse. Time axis is in seconds.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Summary of left ventricular contractility measurements
Heart rate (HR), maximum left ventricular pressure (Max LVP), minimum left ventricular pressure (Min LVP), maximum dP/dt (Max dP/dt), and minimum dP/dt (Min dP/dt) are shown for both wild types and beta 1/beta 2-AR knockouts under anesthetized and awakening conditions. Wild type, n = 5; beta 1/beta 2 knockouts, n = 6.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The beta -ARs are recognized as important components of the sympathetic nervous system, playing critical roles in the maintenance of cardiac, vascular, and metabolic homeostatic mechanisms. The purpose of these studies was to delineate the subtype-specific contributions of the beta 1-AR and beta 2-AR on these physiological processes by genetic knockout techniques, where beta 1- and beta 2-ARs were knocked out individually as well as in combination. By inference, we have also investigated cardiovascular functions specific to the remaining beta 3-AR. Surprisingly, total elimination of both beta 1- and beta 2-ARs has little impact on resting cardiovascular tone or basal metabolism, although functional deficits are clearly revealed when mice are stimulated by beta -AR agonists or maximal exercise. Such results underscore the notion that the beta -ARs are modulators of these physiologic functions but not intrinsic to or required for the functions themselves.

Basal Cardiovascular Function-- Loss of both beta 1- and beta 2-ARs has minimal impact on basal heart rate and blood pressure. Based on the phenotype of both the beta 1-AR knockout (13, 18) and the beta 2-AR knockout (17), these results are not surprising. Such results would be unexpected, however, when considered in the context of numerous pharmacological studies using either non-selective or selective beta -AR antagonists that are commonly used to lower heart rate and blood pressure. Why do mice lacking both adrenergic receptors fail to exhibit abnormalities at rest? First, there may be fundamental differences between animals that lack a given receptor from conception onwards and animals treated with antagonists at a discrete point in time. Furthermore, the bulk of evidence from knock-outs of the alpha 1b-, alpha 2a-, alpha 2b, alpha 2c-, and beta 3-ARs also reveals that basal physiological functions are not significantly perturbed, again failing to reproduce the phenotypes observed by acute subtype-specific blockade in normal animals (25). Our data suggest that there are alternative control points for such critical physiological functions such as cardiac rate and contractility, vascular tone, and metabolic state, which can be altered to compensate for the lack of beta -AR signaling. The parasympathetic nervous system, which acts in functional opposition to signals generated by the sympathetic nervous system (26, 27), has the potential to compensate for absent beta -AR signaling, as do a variety of other hormone or neurotransmitter systems. Our demonstration that cardiac muscarinic receptor density is reduced in the beta 1/beta 2-AR double knockout may reflect a counterbalancing reduction in a receptor that is known to functionally antagonize stimulatory beta -ARs.

beta 3-AR Function-- Another example of a compensatory change in G-protein-coupled receptor signaling resulting from beta 1- and beta 2-AR deficiency is the supranormal response of beta 1/beta 2-AR knockouts to the beta 3-AR agonist CL316243. Stimulation of beta 3-ARs by this agonist (and 37344 from Life Technologies, Inc.) in rats and dogs elicits sustained decreases in both blood pressure and total peripheral resistance (20). In wild type mice, we have demonstrated that beta 3-AR stimulation also results in a robust and sustained hypotensive response. Mice deficient in both beta 1- and beta 2-ARs show an exaggerated response to CL316243. There are several possible explanations for such altered responses. First, vascular beta 3-ARs may be up-regulated in the beta 1-/beta 2-AR double knockout. The demonstration that beta 1-ARs are up-regulated in adipose tissue of beta 3-AR knockout mice (12) supports the contention that deficiencies in beta -AR signaling can be counteracted by increases in the density and/or signaling efficiency of other beta -AR subtypes. Another possibility is that there is an up-regulation of the signaling machinery distal to beta -ARs in the vascular beds of beta 1-/beta 2-AR double knockouts, secondary to disuse. The phenomenon of beta -AR supersensitization following prolonged beta -AR antagonist therapy is well known (28-30) and may be analogous to the situation in mice when both beta 1- and beta 2-ARs are absent.

Experiments with the beta 3-AR agonist CL316243 demonstrate that residual responses (defined as the additional isoproterenol-induced vasodilatory response during full beta 3-AR stimulation) of beta 1-ARs differ from that of beta 2-ARs in mice which lack one or the other subtype. In these experiments, beta 1-AR knock-outs possess identical residual isoproterenol responses in comparison to wild types, whereas beta 2-AR knockouts showed attenuated residual responses. This could be due to either increased efficacy of the beta 2-AR in mediating vasodilatation, different mechanism(s) of receptor activation, or to differences in the distribution among the three beta -ARs within vascular beds. As an example, preferential distribution of beta 2-ARs in small resistance arterioles and beta 1-ARs in large conductance vessels would tend to favor beta 2-ARs in the primary control of peripheral vascular resistance. Additionally, the attenuated response of beta 2-AR knockouts to isoproterenol in these experiments could indicate an overlap of beta 1- and beta 3-AR expression in the same vascular beds, such that beta 3-AR stimulation with CL316243 precludes a maximal response through beta 1-ARs co-expressed in the same resistance vessels.

Metabolic and Physiologic Response to Exercise-- The ability of beta -AR antagonists to alter the metabolic response to exercise is well known (31-33). beta -AR activation normally stimulates glycogenolysis as well as lipolysis, reflected in the rise of plasma glucose and free fatty acids during exercise. Whereas free fatty acid mobilization is impaired in beta -AR-blocked exercising subjects, glycogen utilization is unimpaired, and there appears to be no change in the glucagon response (31-33). In addition to the increased mobilization of metabolic fuels, there are a variety of downstream effectors of beta -AR stimulation that can contribute to increased metabolic demands as follows: adenylate cyclase, the Na+/K+-ATPase, and the L-type Ca2+ channel are all activated by beta -AR stimulation (34-36). Thus, it is not surprising that metabolic demands are reduced in beta 1-/beta 2-AR knockout mice during exercise, although it is surprising that these mice show no impairment of total exercise capacity when run to exhaustion. It is interesting to note that the metabolic alteration seen in beta 1-/beta 2-AR double knockouts appears to result from combined beta 1- and beta 2-AR deficiency, as neither single beta 1- nor beta 2-AR knockouts display the same degree of metabolic hypo-responsiveness during exercise. In humans, such metabolic responses were traditionally thought to be regulated primarily by the beta 2-AR (31), although there are instances where both beta 1- and beta 2-ARs appear to be involved in the metabolic response to exercise (37, 38). Our results in mice suggest that both the beta 1- and beta 2-AR normally subserve redundant metabolic functions in vivo and that both receptor subtypes must be eliminated before significant defects are manifested.

The study of receptor pharmacology in conscious animals is frequently complicated by responses that are either indirect or reflexive in nature. In the present study, the chronotropic effect of isoproterenol in the beta 1-/beta 2-AR double knockout is almost completely eliminated by pretreatment with atropine and thus must be primarily a reflex response to beta 3-AR-mediated vasodilatation. In a previous study using atropine, we demonstrated that ~50% of the typical heart rate response to isoproterenol in conscious mice is due to parasympathetic withdrawal, and ~50% is due to direct beta 1-AR stimulation (18). A reflex mechanism for beta 3-AR stimulation of heart rate is supported by studies in dogs (20) and by our own studies on isolated atria, in which beta 1-/beta 2-AR knockout preparations fail to demonstrate any direct inotropic or chronotropic effects from either isoproterenol or the beta 3-AR agonist CL316243. In some instances, we were not able to block completely the baroreflex with atropine, as evidenced by the bradycardic effect of epinephrine in the beta 1-/beta 2-AR double knockouts. These results suggest that either atropine dosage was not sufficiently high to block the increase in vagal tone following a hypertensive stimulus or that an alpha -AR component of the action of epinephrine has negative chronotropic effects. The failure to demonstrate significant chronotropic or inotropic effects of agents such as histamine or serotonin, despite their ability to stimulate cardiac adenylate cyclase in vitro (39, 40), suggests that beta -ARs are the primary G-protein-coupled receptors regulating cardiac function in vivo.

Given that both beta 1-AR knockouts (18) and the beta 1-/beta 2-AR double knockout show normal exercise capacities at submaximal heart rates, we wanted to investigate whether there were any significant differences in cardiac inotropic state that could represent an adaptation to the loss of beta -ARs. Based on our previous findings with beta 1-AR knockouts (13, 41), the inotropic state is largely determined by the presence or absence of the beta 1-AR and any underlying sympathetic tone. Our results here suggest that there may be some residual sympathetic tone in anesthetized mice, which in wild type mice manifests itself as an increased +dP/dt and decreased -dP/dt in comparison to the beta 1/beta 2-AR double knockout; this is even further accentuated in the awakening state. Alternatively, the difference in heart rates between wild types and double knockout mice during anesthesia and upon awakening could be responsible for this difference in dP/dt. Interestingly, inotropic state is greatly enhanced even in beta 1/beta 2-AR double knockouts upon transition from anesthetized to awakening states. Depression of myocardial contractility while under isoflurane anesthesia can be due to indirect effects to reduce sympathetic outflow, as well as direct inhibitory effects on cardiac muscle (42-44). Despite the reduced positive and negative dP/dt values in beta 1/beta 2-AR double knockouts, these mice develop equivalent peak left ventricular pressures in comparison to their wild type counterparts. Taken together with the exercise studies, our results would suggest that the beta -AR-mediated increases in heart rate and contractility in the mouse are not necessary for maximal performance during a stress such as exercise. In fact, at the extremely high heart rates typical for a mouse at maximal exercise, reduced diastolic filling time may serve to limit any further increases in cardiac output. The demonstration that humans under beta -AR blockade can increase stroke volume via the Frank-Starling mechanism (while heart rate remains depressed) supports the idea that chronotropic and inotropic stimulation through beta -ARs are not required for maximal exercise performance (45). Other studies have shown that during exercise, intrinsic mechanisms such as increased venous return enhances diastolic filling and hence cardiac output (46, 47) and can be preferentially utilized over heart rate changes in some pathological states to maintain cardiac output (48). Together with our data in genetically altered mice, such results underscore the importance of intrinsic preload and afterload mechanisms and tend to mitigate the requirement for beta -AR signaling in the adaptive responses to exercise.

In summary, the present study has further characterized the physiological role of beta 1- and beta 2-ARs in mice by means of genetic knockout techniques. The impact of beta 1-, beta 2-, or beta 1/beta 2-AR loss on basal physiological functions such as heart rate, blood pressure, or metabolic rate is remarkably minor; however, striking differences between these knockouts and their wild type counterparts can be seen following beta -agonist administration or during the stresses of exercise. Given what is known about the important role that beta 1- and beta 2-ARs play in both physiological and pathophysiological processes, one can speculate as to whether the gene knockout technique has revealed the "true" role of these receptor subtypes. More thorough studies involving different types of stresses (such as induced heart failure) and longitudinal studies will help to clarify this issue. Despite the limitations of the model systems studied to date, certain beta -AR-modulated functions such as heart rate and contractility are well defined and can be attributed to single beta -AR members (in this case the beta 1-AR). Other functions, such as beta -AR-mediated vasodilatation, are additive and integrated, with all three beta -AR subtypes contributing at some level. For other functions, such as metabolic rate, beta -AR actions appear to be redundant, and deficiencies are not apparent until both beta -AR subtypes are knocked out. Mice lacking beta 1- and/or beta 2-ARs represent useful model systems for the study of beta -AR-modulated function in vivo, as well as the role that beta -ARs play in pathophysiology.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Supported in part by Medical Scientist Training Program Training Grant GM07365 from the NIGMS, National Institutes of Health.

** To whom correspondence should be addressed: Howard Hughes Medical Institute, Stanford University, Stanford, CA 94305. Tel.: 650-723-7069; Fax: 650-498-5092; E-mail: kobilka{at}cmgm.stanford.edu.

    ABBREVIATIONS

The abbreviations used are: beta -Ar(s), beta -adrenergic receptor(s); GTE, graded treadmill exercise; Iso, isoproterenol.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
  1. Strader, C. D., Fong, T. M., Graziano, M. P., and Tota, M. R. (1995) FASEB J. 9, 745-754[Abstract/Free Full Text]
  2. Pepperl, D. J., and Regan, J. W. (1994) in Handbook of Receptors and Channels (Peroutka, S. J., ed), pp. 45-78, CRC Press, Inc., Boca Raton, FL
  3. Dixon, R. A., Kobilka, B. K., Strader, D. J., Benovic, J. L., Dohlman, H. G., Frielle, T., Bolanowski, M. A., Bennett, C. D., Rands, E., Diehl, R. E., Mumford, R. A., Slater, E. E., Sigal, I. S., Caron, M. G., Lefkowitz, R. J., and Strader, C. D. (1986) Nature 321, 75-79[Medline] [Order article via Infotrieve]
  4. Frielle, T., Collins, S., Daniel, K. W., Caron, M. G., Lefkowitz, R. J., and Kobilka, B. K. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 7920-7924[Abstract]
  5. Emorine, L. J., Marullo, S., Briend-Sutren, M., Patey, G., Tate, K., Delavier-Klutchko, C., and Strosberg, A. D. (1989) Science 245, 1118-1121[Medline] [Order article via Infotrieve]
  6. Strosberg, A. D. (1995) Obes. Res., Suppl. 4, 501S-505S
  7. Rohrer, D. K. (1998) in From Hypertension to Heart Failure (Bohm, M., Laragh, J. H., and Zehender, M., eds), pp. 129-158, Springer-Verlag, Berlin
  8. Lands, A. M., Luduena, F. P., and Buzzo, H. J. (1967) Life Sci. 6, 2241-2249[CrossRef][Medline] [Order article via Infotrieve]
  9. Lands, A. M., Arnold, A., McAuliff, J. P., Luduena, F. P., and Brown, T. J. (1967) Nature 214, 597-598[Medline] [Order article via Infotrieve]
  10. Malinowska, B., and Schlicker, E. (1997) Br. J. Pharmacol. 122, 1307-1314[Abstract]
  11. Link, R. E., Stevens, M. S., Kulatunga, M., Scheinin, M., Barsh, G. S., and Kobilka, B. K. (1995) Mol. Pharmacol. 48, 48-55[Abstract]
  12. Susulic, V. S., Frederich, R. C., Lawitts, J., Tozzo, E., Kahn, B. B., Harper, M. E., Himms-Hagen, J., Flier, J. S., and Lowell, B. B. (1995) J. Biol. Chem. 270, 29483-29492[Abstract/Free Full Text]
  13. Rohrer, D. K., Desai, K. H., Jasper, J. R., Stevens, M. E., Regula, D. J., Barsh, G. S., Bernstein, D., and Kobilka, B. K. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7375-7380[Abstract/Free Full Text]
  14. Link, R. E., Desai, K., Hein, L., Stevens, M. E., Chruscinski, A., Bernstein, D., Barsh, G. S., and Kobilka, B. K. (1996) Science 273, 803-805[Abstract]
  15. MacMillan, L. B., Hein, L., Smith, M. S., Piascik, M. T., and Limbird, L. E. (1996) Science 273, 801-803[Abstract]
  16. Cavalli, A., Lattion, A., Hummler, E., Nenninger, M., Pedrazzini, T., Aubert, J., Michel, M. C., Yang, M., Lembo, G., Vecchione, C., Mostardini, M., Schmidt, A., Beermann, F., and Cotecchia, S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 11589-11594[Abstract/Free Full Text]
  17. Chruscinski, A. J., Rohrer, D. K., Schauble, E., Desai, K. H., Bernstein, D., and Kobilka, B. K. (1999) J. Biol. Chem. 274, 16694-16700[Abstract/Free Full Text] (acc art 568292)
  18. Rohrer, D. K., Schauble, E. H., Desai, K. H., Kobilka, B. K., and Bernstein, D. (1998) Am. J. Physiol. 274, H1184-H1193[Medline] [Order article via Infotrieve]
  19. Desai, K. H., Sato, R., Schauble, E., Barsh, G. S., Kobilka, B. K., and Bernstein, D. (1997) Am. J. Physiol. 272, H1053-H1061[Abstract/Free Full Text]
  20. Shen, Y. T., Cervoni, P., Claus, T., and Vatner, S. F. (1996) J. Pharmacol. Exp. Ther. 278, 1435-1443[Abstract]
  21. Cline, W. J. (1981) J. Pharmacol. Exp. Ther. 216, 104-110[Abstract]
  22. Davy, M., Grandcourt, O., Midol-Monnet, M., and Cohen, Y. (1997) Cell. Mol. Life Sci. 53, 263-266[Medline] [Order article via Infotrieve]
  23. Zaizen, H., Imanishi, S., Nasu, M., and Arita, M. (1996) Heart Vessels 11, 10-17[Medline] [Order article via Infotrieve]
  24. Gauthier, C., Tavernier, G., Charpentier, F., Langin, D., and Le, M. H. (1996) J. Clin. Invest. 98, 556-562[Abstract/Free Full Text]
  25. Rohrer, D. K., and Kobilka, B. K. (1998) Annu. Rev. Pharmacol. Toxicol. 38, 35-73
  26. Endoh, M. (1989) Basic Res. Cardiol. 1, 69-83
  27. Eschenhagen, T., Mende, U., Diederich, M., Hertle, B., Memmesheimer, C., Pohl, A., Schmitz, W., Scholz, H., Steinfath, M., Bohm, M., Michel, M. C., Brodde, O. E., and Raap, A. (1996) Circulation 93, 763-771[Abstract/Free Full Text]
  28. Glaubiger, G., and Lefkowitz, R. J. (1977) Biochem. Biophys. Res. Commun. 78, 720-725[Medline] [Order article via Infotrieve]
  29. Boudoulas, H., Lewis, R. P., Kates, R. E., and Dalamangas, G. (1977) Ann. Intern. Med. 87, 433-436[Medline] [Order article via Infotrieve]
  30. Brodde, O. E., Michel, M. C., Wang, X. L., and Zerkowski, H. R. (1988) J. Hypertens. 6 (suppl.), 497-500
  31. Opie, L. H. (1985) Am. J. Cardiol. 55, 95D-100D[CrossRef][Medline] [Order article via Infotrieve]
  32. Galbo, H., Holst, J. J., Christensen, N. J., and Hilsted, J. (1976) J. Appl. Physiol. 40, 855-863[Abstract/Free Full Text]
  33. Juhlin, D. A. (1983) Acta Med. Scand. 672 (suppl.), 49-54
  34. Rogus, E. M., Cheng, L. C., and Zierler, K. (1977) Biochim. Biophys. Acta 464, 347-355[Medline] [Order article via Infotrieve]
  35. Clausen, T., and Flatman, J. A. (1977) J. Physiol. (Lond.) 270, 383-414[Medline] [Order article via Infotrieve]
  36. Ellingsen, O., Sejersted, O. M., Leraand, S., and Ilebekk, A. (1987) Circ. Res. 60, 540-550[Abstract]
  37. Uusitupa, M., Siitonen, O., Harkonen, M., Gordin, A., Aro, A., Hersio, K., Johansson, G., Korhonen, T., and Rauramaa, R. (1982) Ann. Clin. Res. 34, 165-167
  38. McLeod, A. A., Brown, J. E., Kuhn, C., Kitchell, B. B., Sedor, F. A., Williams, R. S., and Shand, D. G. (1983) Circulation 67, 1076-1084[Abstract]
  39. Bristow, M. R., Cubicciotti, R., Ginsburg, R., Stinson, E. B., and Johnson, C. (1982) Mol. Pharmacol. 21, 671-679[Abstract]
  40. Brodde, O. E., Broede, A., Daul, A., Kunde, K., and Michel, M. C. (1992) Basic Res. Cardiol. 1, 1-14
  41. Desai, K. H., Rohrer, D. K., Kobilka, B. K., and Bernstein, D. (1996) Circulation. 94,Suppl. 1, I-288
  42. Kemmotsu, O., Hashimoto, Y., and Shimosato, S. (1973) Anesthesiology 39, 470-477[Medline] [Order article via Infotrieve]
  43. Lynch, C. D. (1986) Anesthesiology 64, 620-631[Medline] [Order article via Infotrieve]
  44. Bosnjak, Z. J., Supan, F. D., and Rusch, N. J. (1991) Anesthesiology 74, 340-345[Medline] [Order article via Infotrieve]
  45. Bevilacqua, M., Savonitto, S., Bosisio, E., Chebat, E., Bertora, P. L., Sardina, M., and Norbiato, G. (1989) Am. J. Cardiol. 63, 853-857[Medline] [Order article via Infotrieve]
  46. Gotshall, R. W., Bauer, T. A., and Fahrner, S. L. (1996) Int. J. Sports Med. 17, 17-21[Medline] [Order article via Infotrieve]
  47. Di Bello, V., Talarico, L., Di, M. C., Santoro, G., Bertini, A., Giorgi, D., Caputo, M. T., Bianchi, M., Cecchini, L., and Giusti, C. (1995) Int. J. Sports Med. 16, 498-506[Medline] [Order article via Infotrieve]
  48. Thomas, A. J., Davis, G. M., and Sutton, J. R. (1997) Methods Inf. Med. 36, 372-375[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.